GlassScriptPhysician profile
Scott L Holwerda
NPI 1285954024
$3,815.82
in general payments reported to CMS, 2019-2025
50 companies · $101 in 2025
The $101 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,111 · 2020: $457 · 2021: $392 · 2022: $689 · 2023: $662 · 2024: $405 · 2025: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,167.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $613.86 | 2019-2025 | |
| Amgen INC. | $349.79 | 2019-2023 | Evenity, Prolia, Repatha |
| Astrazeneca Pharmaceuticals LP | $242.47 | 2019-2024 | Airsupra, Breztri |
| Glaxosmithkline, LLC. | $198.06 | 2019-2024 | Shingrix, Trelegy Ellipta |
| Novo Nordisk INC | $154.95 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $150.04 | 2019-2024 | Jardiance, Synjardy |
| Pfizer INC. | $147.71 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $138.42 | 2019-2024 | |
| Abbott Laboratories | $128.73 | 2021-2023 | Freestyle Libre 3 |
| Lilly USA, LLC | $113.74 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Dexcom, INC. | $108.45 | 2022-2024 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $98.77 | 2019-2023 | Veozah |
| Radius Health, INC. | $96.80 | 2019-2023 | Tymlos |
| Sunovion Pharmaceuticals INC. | $93.92 | 2019-2020 | |
| Amarin Pharma, INC. | $80.97 | 2020-2021 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Holwerda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.